Merck Kgaa Unsp ADR (MKGAY) 28.9150 $MKGAY
The Zacks Analyst Blog Highlights: Merck KGaA, Lannett, Avanir Pharmaceuticals, Anacor Pharmaceuticals and Helen of Troy
PR Newswire - Tue Sep 16, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Merck KGaA (OTC:MKGAF-Free Report), Lannett Company, Inc. (NYSE:LCI-Free Report), Avanir Pharmaceuticals, Inc. (Nasdaq:AVNR-Free Report), Anacor Pharmaceuticals, Inc. (Nasdaq:ANAC-Free Report) and Helen of Troy Limited (Nasdaq:HELE-Free Report).
EMD Millipore Recognized for Technologically Advanced Products by R&D Magazine
Business Wire - Mon Sep 15, 7:00AM CDT
EMD Millipore, the Life Science division of Merck KGaA, announced it has received two R&D Magazine 100 Awards for innovative products released to market in 2014. The 52nd Annual R&D Awards recognize the 100 most technologically significant products introduced into the marketplace over the past year.
Merck KGaA Discontinues Clinical Development Program of Tecemotide as a Monotherapy in Stage III Non-Small Cell Lung Cancer
CNW Group - Fri Sep 12, 9:54AM CDT
Merck KGaA, Darmstadt, Germany, announced today that its biopharmaceutical division will discontinue the clinical development program of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) as a monotherapy in Stage III non-small cell lung cancer (NSCLC).
EMD Serono Honors Recipients of the Second Annual EUR 1 Million Grant for Multiple Sclerosis Innovation
PR Newswire - Fri Sep 12, 7:00AM CDT
EMD Serono Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the recipients of the second annual Grant for Multiple Sclerosis Innovation (GMSI) at the 2014 Joint ACTRIMS-ECTRIMS Meeting of the Americas Committee for Treatment and Research in MS (ACTRIMS) and European Committee for Treatment and Research in MS (ECTRIMS), taking place September 10-13, in Boston, U.S.A.
Global and Chinese Sodium Fluoride Industry Report 2014-2019
M2 - Thu Sep 11, 8:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2jddzp/global_and) has announced the addition of the "Global and Chinese Sodium Fluoride Industry Report 2014" report to their offering. The Global and Chinese Sodium Fluoride Industry Report 2014 is a professional and in-depth study on the current state of the global sodium fluoride industry with a focus on the Chinese situation. The report provides an overview of the industry including definitions, classifications, applications and industry chain structure. The sodium fluoride market analysis is provided for both the international and Chinese domestic situations including development trends, competitive landscape analysis, key regions development status and a comparison analysis between the international and Chinese markets. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. Sodium fluoride industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. The report focuses on sixteen industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The sodium fluoride industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered: - Sodium Fluoride Industry Overview - Sodium Fluoride International and China Market Analysis - Sodium Fluoride Development Environmental Analysis - Sodium Fluoride Development Policy and Plan - Sodium Fluoride Manufacturing Process and Cost Structure - 2009-2014 Sodium Fluoride Productions Supply Sales Demand Market Status and Forecast - Sodium Fluoride Key Manufacturers Analysis - Up and Down Stream Industry Analysis - Sodium Fluoride Marketing Channels Analysis - Sodium Fluoride Industry Development Trend - Sodium Fluoride Industry Development Proposals - Sodium Fluoride New Project Investment Feasibility Analysis - Global and China Sodium Fluoride Industry Research Conclusions Companies Mentioned - Au Xiang chemical - CRYSTRAN LTD - Chaling Xinyu - Do-Fluoride Chemicals - Honywell - Hunan Guangcheng - Jia Hong Chemical - Jinan chemical works branch - Merck KGaA - ORICA Chemical - Prayon - Shandong Xingfu - Solvay - WASUN Group - Youxian Shengli - Youxian Xinxing For more information visit http://www.researchandmarkets.com/research/2jddzp/global_and
EMD Serono and Accelerated Cure Project Launch Collaborative Research Program to Optimize Treatment and Understand Progression of Multiple Sclerosis
PR Newswire - Wed Sep 10, 8:00AM CDT
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany and the Accelerated Cure Project for Multiple Sclerosis today announced a lead founding sponsor agreement to help launch the Optimizing Treatment--Understanding Progression (OPT-UP) study.
EMD Serono Presents New Data on Rebif ® (Interferon beta-1a) and Multiple Sclerosis Pipeline at Joint ACTRIMS-ECTRIMS Meeting in Boston
PR Newswire - Tue Sep 09, 2:00PM CDT
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that new data from the division's multiple sclerosis (MS) portfolio will be presented at ACTRIMS-ECTRIMS 2014, the joint meeting of the Americas Committee for Treatment and Research in MS (ACTRIMS) and European Committee for Treatment and Research in MS (ECTRIMS), taking place September 10-13 in Boston, U.S.A.
EMD Serono and Massachusetts General Hospital Collaborate to Better Understand Systemic Lupus Erythematosus and Lupus Nephritis
Business Wire - Tue Sep 02, 8:00AM CDT
EMD Serono Research and Development Institute, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, entered into a collaborative research agreement with Massachusetts General Hospital (MGH) to further the understanding of Systemic Lupus Erythematosus and Lupus Nephritis pathogenesis.
EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology
PR Newswire - Tue Sep 02, 8:00AM CDT
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that Drew Young has joined the company as Senior Vice President, Neurology and Immunology. In this capacity, he will be responsible for leading the strategic direction of the U.S. Neurology and Immunology franchise, including future products.
The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies
PR Newswire - Thu Aug 28, 10:30AM CDT
Decision Resources Group finds that the market for colorectal cancer (CRC) therapies will remain constant, at around $7.7 billion by 2023 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The biosimilar erosion of Roche/Genentech/Chugai's Avastin and Bristol-Myers Squibb/Eli Lilly/Merck KGaA's Erbitux will be balanced out by the launch of Eli Lilly's Cyramza, Taiho Pharmaceutical's Lonsurf, Alchemia's HA-irinotecan and Boehringer Ingelheim's Vargatef, as well as increased uptake of Sanofi/Regeneron's Zaltrap and Amgen/Takeda's Vectibix.
Compact, Easy-to-Use Steritest(TM) Symbio Pumps from EMD Millipore Leverage Industry Leading Technology for Improved Sterility Testing
PR Newswire - Thu Aug 28, 7:00AM CDT
EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, has launched Steritest(TM) Symbio Pumps for easier, safer and more reliable sterility testing of pharmaceutical products in laminar flow hoods, isolators and clean rooms. The Steritest(TM) Symbio Pumps were developed to address stringent pharmaceutical testing requirements. The launch continues EMD Millipore's 40 year legacy of providing groundbreaking sterility testing products.
Oncothyreon (ONTY) Slumps, Tecemotide Fails Phase I/II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 2:53PM CDT
Shares of Oncothyreon Inc. (ONTY) slumped significantly after collaboration partner Germany-based Merck KGaA (MKGAY) informed the former that a phase I/II study, on tecemotide, did not meet its primary endpoint.
Global Pigments and Dyes Markets 2014-2020 - Strategic Business Report
M2 - Fri Aug 15, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sdvr9x/pigments_and_dyes) has announced the addition of the "Pigments and Dyes - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. This report analyzes the worldwide markets for Pigments and Dyes in Thousand Tons and US$ Million by the following Product Segments: - Dyes (Acid Dyes, Basic Dyes, Direct Dyes, Disperse Dyes, Fiber Reactive Dyes, Vat Dyes, Fluorescent Brighteners, & Other Dyes) - Inorganic Pigments (Titanium Dioxide, Iron Oxides, & Other Inorganic Pigments), and Organic Pigments. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 308 companies including many key and niche players such as: - ALTANA AG - BASF SE - Cathay Pigments, Inc. - Clariant International Limited - DIC Corporation - Sun Chemical Corporation - Dainichiseika Color & Chemicals Mfg. Co., Ltd. - E.I. du Pont de Nemours and Company - Ferro Corp - Flint Group - Heubach GmbH - Huntsman International, LLC - Ishihara Corporation - Kemira Oyj - Kronos Worldwide, Inc. - Lanxess AG - Merck KGAA - Silberline Manufacturing Co., Inc. - The Shepherd Color Company - Toyo Ink SC Holdings Co., Ltd. - Tronox, Inc Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Market Trends, Issues & Drivers 3. Exports And Import Statistics 4. Product Overview 5. Product Introductions/Innovations 6. Recent Industry Activity 7. Focus On Select Global Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 308 (including Divisions/Subsidiaries 321) - The United States (40) - Canada (2) - Japan (12) - Europe (98) - France (3) - Germany (28) - The United Kingdom (16) - Italy (14) - Spain (
- Rest of Europe (29) - Asia-Pacific (Excluding Japan) (164) - Latin America (2) - Africa (1) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/sd...s_and_dyes
China Pharmaceutical Guide 2014 - 9th Edition Out Now
M2 - Tue Aug 12, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qbjpjg/china) has announced the addition of the "China Pharmaceutical Guide 2014 (9th Edition)" report to their offering. Written by veteran pharma industry executives to help guide international players navigate through thecomplex and turbulent Chinese healthcare business environment, it is the most authoritative reference on China's pharmaceutical and healthcare business. Extensive coverage on China's pharma industry and healthcare sector, structure and market environment, regulatory framework, healthcare provision and financing, disease & drug consumption patterns, pharma sales, marketing & distribution, trends and opportunities, market entry strategies, case studies of successes and failures in six key areas of the Chinese pharma business, and profiles of leading MNC pharma players in China. The 2014 edition has been thoroughly updated with significantly expanded coverage in recent editions on more sub-sectors, outsourcing, clinical practices, regulatory updates on healthcare reform and drug policies, additional case studies, and latest market / health data updated through mid-2014. Key Topics Covered: Part I Overview Of The Chinese Economy And Business Part II The Chinese Pharmaceutical Industry And Market Part III Pharmaceutical Regulatory Framework Part IV Healthcare Provision And Financing Part V Disease And Drug Consumption Patterns Part VI Pharmaceutical Sales, Marketing And Distribution In China Part VII Contemporary Trends, Opportunities And Strategic Considerations Part VIII Market Entry Strategies And Execution Part IX Mini Case Studies Part X Company Profiles: Multinational Pharma Companies In China Companies Mentioned - Abbvie China (Abbott) - Astellas China - AstraZeneca China - Baxter Healthcare China - Bayer Healthcare China - Beaufour Ipsen China - Boehringer Ingelheim China - Bristol-Myers Squibb China - DSM China - Daiichi Sankyo China - Dainippon Sumitomo Pharma China - Eisai China - Eli Lilly China - Fresenius Kabi China - GE Healthcare China - GlaxoSmithKline China - Johnson & Johnson China - Kyowa Hakko Kirin China - Merck KGAA/Merck Serono China - Merck Sharp & Dhome China - Mitsubishi Tanabe Pharma China - Novartis China - Novo Nordisk China - Otsuka China - Pfizer China - Roche China - Sanofi China - Stada China - TEVA China - Takeda China For more information visit http://www.researchandmarkets.com/research/qbjpjg/china
AWARE for All Clinical Research Education Day Returns To Boston
PR Newswire - Mon Aug 04, 12:35PM CDT
The Center for Information and Study on Clinical Research Participation (CISCRP) is pleased to announce the return of AWARE for All Boston, a free event designed to promote understanding and dialogue around clinical research participation. The event will be hosted at the Curry Student Center Ballroom at Northeastern University on Monday, October 27th from 5PM to 8PM and will feature free health screenings, informational exhibits, meaningful presentations from prominent Boston medical professionals and community patients involved in clinical research, as well as free food and giveaways. Funding for this event is provided by CISCRP's national AWARE sponsor EMD Serono, Inc., a subsidiary of Merck KGaA Darmstadt, Germany, and local sponsors Harvard School of Public Health, The Fenway Institute, Fenway Health, and Brigham & Women's Hospital, section of diabetes.
Ready-to-Use EZ-Fit(TM) Filtration Unit from EMD Millipore Leverages Industry Leading Technology for More Efficient Bioburden Testing of Liquids
PR Newswire - Wed Jul 30, 6:00AM CDT
EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, has launched the EZ-Fit(TM) Filtration Unit, a ready-to-use, disposable filtration device for bioburden testing. The system is more efficient than traditional methods, resulting in increased reliability and streamlined workflows. The unit, which conforms to international standards (USP/EP) and water testing regulations, can be used for filtration of liquid samples including water, raw materials, in-process samples and final products.
Ready-to-Use EZ-Fit(TM) Filtration Unit from EMD Millipore Leverages Industry Leading Technology for More Efficient Bioburden Testing of Municipal Water, Environmental Samples and Beverages
PR Newswire - Wed Jul 30, 6:00AM CDT
EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, has launched the EZ-Fit(TM) Filtration Unit, a ready-to-use, disposable filtration device for bioburden testing. The system is faster and more efficient than traditional methods, resulting in increased reliability and streamlined workflows. The unit, which conforms to international standards (USP/EP) and water testing regulations, can be used for filtration of liquid samples including water, raw materials, in-process samples and final products.
EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma
CNW Group - Tue Jul 29, 1:30AM CDT
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the initiation of an international Phase II study designed to assess the efficacy and safety of MSB0010718C, an investigational fully human IgG1 monoclonal antibody that binds to programmed death-ligand 1 (PD-L1). This multicenter, single-arm, open-label study is being conducted in patients with metastatic Merkel cell carcinoma (mMCC), a rare and aggressive type of skin tumor,([)(1)(])(,)([)(2)(]) who have previously received one line of chemotherapy. It is expected to recruit 84 patients across Asia Pacific, Australia, Europe and North America. The primary endpoint of the study is overall response.
Pipeline Analysis and Sales Projections of the Top 25 Pharmaceutical Companies 2013-2023
M2 - Wed Jul 23, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7pjm9m/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. The companies included in the study are: - Pfizer, inc. - Novartis AG - Roche ltd. - Merck & Co., inc. - Sanofi - Glaxosmithkline PLC - Johnson & johnson - Astra Zeneca plc - Eli Lilly and Company - Abbvie, inc. - Teva Pharmaceutical Industries, Ltd. - Amgen, inc. - Bristol-myers Squibb Company - Takeda Pharmaceutical co., LTD - Bayer AG - Novo nordisk - Boehringer Ingelheim gmbh - Daiichi Sankyo - Astellas - Gilead Sciences - Otsuka Pharmaceutical - Merck KGAA - Actavis - Mylan - Baxter international For more information visit http://www.researchandmarkets.com/research/7pjm9m/top_25
The Zacks Analyst Blog Highlights: Merck KGaA, Lannett, Avanir Pharmaceuticals, Anacor Pharmaceuticals and Helen of Troy
PR Newswire - Tue Sep 16, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Merck KGaA (OTC:MKGAF-Free Report), Lannett Company, Inc. (NYSE:LCI-Free Report), Avanir Pharmaceuticals, Inc. (Nasdaq:AVNR-Free Report), Anacor Pharmaceuticals, Inc. (Nasdaq:ANAC-Free Report) and Helen of Troy Limited (Nasdaq:HELE-Free Report).
EMD Millipore Recognized for Technologically Advanced Products by R&D Magazine
Business Wire - Mon Sep 15, 7:00AM CDT
EMD Millipore, the Life Science division of Merck KGaA, announced it has received two R&D Magazine 100 Awards for innovative products released to market in 2014. The 52nd Annual R&D Awards recognize the 100 most technologically significant products introduced into the marketplace over the past year.
Merck KGaA Discontinues Clinical Development Program of Tecemotide as a Monotherapy in Stage III Non-Small Cell Lung Cancer
CNW Group - Fri Sep 12, 9:54AM CDT
Merck KGaA, Darmstadt, Germany, announced today that its biopharmaceutical division will discontinue the clinical development program of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) as a monotherapy in Stage III non-small cell lung cancer (NSCLC).
EMD Serono Honors Recipients of the Second Annual EUR 1 Million Grant for Multiple Sclerosis Innovation
PR Newswire - Fri Sep 12, 7:00AM CDT
EMD Serono Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the recipients of the second annual Grant for Multiple Sclerosis Innovation (GMSI) at the 2014 Joint ACTRIMS-ECTRIMS Meeting of the Americas Committee for Treatment and Research in MS (ACTRIMS) and European Committee for Treatment and Research in MS (ECTRIMS), taking place September 10-13, in Boston, U.S.A.
Global and Chinese Sodium Fluoride Industry Report 2014-2019
M2 - Thu Sep 11, 8:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2jddzp/global_and) has announced the addition of the "Global and Chinese Sodium Fluoride Industry Report 2014" report to their offering. The Global and Chinese Sodium Fluoride Industry Report 2014 is a professional and in-depth study on the current state of the global sodium fluoride industry with a focus on the Chinese situation. The report provides an overview of the industry including definitions, classifications, applications and industry chain structure. The sodium fluoride market analysis is provided for both the international and Chinese domestic situations including development trends, competitive landscape analysis, key regions development status and a comparison analysis between the international and Chinese markets. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. Sodium fluoride industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. The report focuses on sixteen industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The sodium fluoride industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered: - Sodium Fluoride Industry Overview - Sodium Fluoride International and China Market Analysis - Sodium Fluoride Development Environmental Analysis - Sodium Fluoride Development Policy and Plan - Sodium Fluoride Manufacturing Process and Cost Structure - 2009-2014 Sodium Fluoride Productions Supply Sales Demand Market Status and Forecast - Sodium Fluoride Key Manufacturers Analysis - Up and Down Stream Industry Analysis - Sodium Fluoride Marketing Channels Analysis - Sodium Fluoride Industry Development Trend - Sodium Fluoride Industry Development Proposals - Sodium Fluoride New Project Investment Feasibility Analysis - Global and China Sodium Fluoride Industry Research Conclusions Companies Mentioned - Au Xiang chemical - CRYSTRAN LTD - Chaling Xinyu - Do-Fluoride Chemicals - Honywell - Hunan Guangcheng - Jia Hong Chemical - Jinan chemical works branch - Merck KGaA - ORICA Chemical - Prayon - Shandong Xingfu - Solvay - WASUN Group - Youxian Shengli - Youxian Xinxing For more information visit http://www.researchandmarkets.com/research/2jddzp/global_and
EMD Serono and Accelerated Cure Project Launch Collaborative Research Program to Optimize Treatment and Understand Progression of Multiple Sclerosis
PR Newswire - Wed Sep 10, 8:00AM CDT
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany and the Accelerated Cure Project for Multiple Sclerosis today announced a lead founding sponsor agreement to help launch the Optimizing Treatment--Understanding Progression (OPT-UP) study.
EMD Serono Presents New Data on Rebif ® (Interferon beta-1a) and Multiple Sclerosis Pipeline at Joint ACTRIMS-ECTRIMS Meeting in Boston
PR Newswire - Tue Sep 09, 2:00PM CDT
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that new data from the division's multiple sclerosis (MS) portfolio will be presented at ACTRIMS-ECTRIMS 2014, the joint meeting of the Americas Committee for Treatment and Research in MS (ACTRIMS) and European Committee for Treatment and Research in MS (ECTRIMS), taking place September 10-13 in Boston, U.S.A.
EMD Serono and Massachusetts General Hospital Collaborate to Better Understand Systemic Lupus Erythematosus and Lupus Nephritis
Business Wire - Tue Sep 02, 8:00AM CDT
EMD Serono Research and Development Institute, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, entered into a collaborative research agreement with Massachusetts General Hospital (MGH) to further the understanding of Systemic Lupus Erythematosus and Lupus Nephritis pathogenesis.
EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology
PR Newswire - Tue Sep 02, 8:00AM CDT
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that Drew Young has joined the company as Senior Vice President, Neurology and Immunology. In this capacity, he will be responsible for leading the strategic direction of the U.S. Neurology and Immunology franchise, including future products.
The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies
PR Newswire - Thu Aug 28, 10:30AM CDT
Decision Resources Group finds that the market for colorectal cancer (CRC) therapies will remain constant, at around $7.7 billion by 2023 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The biosimilar erosion of Roche/Genentech/Chugai's Avastin and Bristol-Myers Squibb/Eli Lilly/Merck KGaA's Erbitux will be balanced out by the launch of Eli Lilly's Cyramza, Taiho Pharmaceutical's Lonsurf, Alchemia's HA-irinotecan and Boehringer Ingelheim's Vargatef, as well as increased uptake of Sanofi/Regeneron's Zaltrap and Amgen/Takeda's Vectibix.
Compact, Easy-to-Use Steritest(TM) Symbio Pumps from EMD Millipore Leverage Industry Leading Technology for Improved Sterility Testing
PR Newswire - Thu Aug 28, 7:00AM CDT
EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, has launched Steritest(TM) Symbio Pumps for easier, safer and more reliable sterility testing of pharmaceutical products in laminar flow hoods, isolators and clean rooms. The Steritest(TM) Symbio Pumps were developed to address stringent pharmaceutical testing requirements. The launch continues EMD Millipore's 40 year legacy of providing groundbreaking sterility testing products.
Oncothyreon (ONTY) Slumps, Tecemotide Fails Phase I/II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 2:53PM CDT
Shares of Oncothyreon Inc. (ONTY) slumped significantly after collaboration partner Germany-based Merck KGaA (MKGAY) informed the former that a phase I/II study, on tecemotide, did not meet its primary endpoint.
Global Pigments and Dyes Markets 2014-2020 - Strategic Business Report
M2 - Fri Aug 15, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sdvr9x/pigments_and_dyes) has announced the addition of the "Pigments and Dyes - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. This report analyzes the worldwide markets for Pigments and Dyes in Thousand Tons and US$ Million by the following Product Segments: - Dyes (Acid Dyes, Basic Dyes, Direct Dyes, Disperse Dyes, Fiber Reactive Dyes, Vat Dyes, Fluorescent Brighteners, & Other Dyes) - Inorganic Pigments (Titanium Dioxide, Iron Oxides, & Other Inorganic Pigments), and Organic Pigments. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 308 companies including many key and niche players such as: - ALTANA AG - BASF SE - Cathay Pigments, Inc. - Clariant International Limited - DIC Corporation - Sun Chemical Corporation - Dainichiseika Color & Chemicals Mfg. Co., Ltd. - E.I. du Pont de Nemours and Company - Ferro Corp - Flint Group - Heubach GmbH - Huntsman International, LLC - Ishihara Corporation - Kemira Oyj - Kronos Worldwide, Inc. - Lanxess AG - Merck KGAA - Silberline Manufacturing Co., Inc. - The Shepherd Color Company - Toyo Ink SC Holdings Co., Ltd. - Tronox, Inc Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Market Trends, Issues & Drivers 3. Exports And Import Statistics 4. Product Overview 5. Product Introductions/Innovations 6. Recent Industry Activity 7. Focus On Select Global Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 308 (including Divisions/Subsidiaries 321) - The United States (40) - Canada (2) - Japan (12) - Europe (98) - France (3) - Germany (28) - The United Kingdom (16) - Italy (14) - Spain (
- Rest of Europe (29) - Asia-Pacific (Excluding Japan) (164) - Latin America (2) - Africa (1) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/sd...s_and_dyes China Pharmaceutical Guide 2014 - 9th Edition Out Now
M2 - Tue Aug 12, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qbjpjg/china) has announced the addition of the "China Pharmaceutical Guide 2014 (9th Edition)" report to their offering. Written by veteran pharma industry executives to help guide international players navigate through thecomplex and turbulent Chinese healthcare business environment, it is the most authoritative reference on China's pharmaceutical and healthcare business. Extensive coverage on China's pharma industry and healthcare sector, structure and market environment, regulatory framework, healthcare provision and financing, disease & drug consumption patterns, pharma sales, marketing & distribution, trends and opportunities, market entry strategies, case studies of successes and failures in six key areas of the Chinese pharma business, and profiles of leading MNC pharma players in China. The 2014 edition has been thoroughly updated with significantly expanded coverage in recent editions on more sub-sectors, outsourcing, clinical practices, regulatory updates on healthcare reform and drug policies, additional case studies, and latest market / health data updated through mid-2014. Key Topics Covered: Part I Overview Of The Chinese Economy And Business Part II The Chinese Pharmaceutical Industry And Market Part III Pharmaceutical Regulatory Framework Part IV Healthcare Provision And Financing Part V Disease And Drug Consumption Patterns Part VI Pharmaceutical Sales, Marketing And Distribution In China Part VII Contemporary Trends, Opportunities And Strategic Considerations Part VIII Market Entry Strategies And Execution Part IX Mini Case Studies Part X Company Profiles: Multinational Pharma Companies In China Companies Mentioned - Abbvie China (Abbott) - Astellas China - AstraZeneca China - Baxter Healthcare China - Bayer Healthcare China - Beaufour Ipsen China - Boehringer Ingelheim China - Bristol-Myers Squibb China - DSM China - Daiichi Sankyo China - Dainippon Sumitomo Pharma China - Eisai China - Eli Lilly China - Fresenius Kabi China - GE Healthcare China - GlaxoSmithKline China - Johnson & Johnson China - Kyowa Hakko Kirin China - Merck KGAA/Merck Serono China - Merck Sharp & Dhome China - Mitsubishi Tanabe Pharma China - Novartis China - Novo Nordisk China - Otsuka China - Pfizer China - Roche China - Sanofi China - Stada China - TEVA China - Takeda China For more information visit http://www.researchandmarkets.com/research/qbjpjg/china
AWARE for All Clinical Research Education Day Returns To Boston
PR Newswire - Mon Aug 04, 12:35PM CDT
The Center for Information and Study on Clinical Research Participation (CISCRP) is pleased to announce the return of AWARE for All Boston, a free event designed to promote understanding and dialogue around clinical research participation. The event will be hosted at the Curry Student Center Ballroom at Northeastern University on Monday, October 27th from 5PM to 8PM and will feature free health screenings, informational exhibits, meaningful presentations from prominent Boston medical professionals and community patients involved in clinical research, as well as free food and giveaways. Funding for this event is provided by CISCRP's national AWARE sponsor EMD Serono, Inc., a subsidiary of Merck KGaA Darmstadt, Germany, and local sponsors Harvard School of Public Health, The Fenway Institute, Fenway Health, and Brigham & Women's Hospital, section of diabetes.
Ready-to-Use EZ-Fit(TM) Filtration Unit from EMD Millipore Leverages Industry Leading Technology for More Efficient Bioburden Testing of Liquids
PR Newswire - Wed Jul 30, 6:00AM CDT
EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, has launched the EZ-Fit(TM) Filtration Unit, a ready-to-use, disposable filtration device for bioburden testing. The system is more efficient than traditional methods, resulting in increased reliability and streamlined workflows. The unit, which conforms to international standards (USP/EP) and water testing regulations, can be used for filtration of liquid samples including water, raw materials, in-process samples and final products.
Ready-to-Use EZ-Fit(TM) Filtration Unit from EMD Millipore Leverages Industry Leading Technology for More Efficient Bioburden Testing of Municipal Water, Environmental Samples and Beverages
PR Newswire - Wed Jul 30, 6:00AM CDT
EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, has launched the EZ-Fit(TM) Filtration Unit, a ready-to-use, disposable filtration device for bioburden testing. The system is faster and more efficient than traditional methods, resulting in increased reliability and streamlined workflows. The unit, which conforms to international standards (USP/EP) and water testing regulations, can be used for filtration of liquid samples including water, raw materials, in-process samples and final products.
EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma
CNW Group - Tue Jul 29, 1:30AM CDT
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the initiation of an international Phase II study designed to assess the efficacy and safety of MSB0010718C, an investigational fully human IgG1 monoclonal antibody that binds to programmed death-ligand 1 (PD-L1). This multicenter, single-arm, open-label study is being conducted in patients with metastatic Merkel cell carcinoma (mMCC), a rare and aggressive type of skin tumor,([)(1)(])(,)([)(2)(]) who have previously received one line of chemotherapy. It is expected to recruit 84 patients across Asia Pacific, Australia, Europe and North America. The primary endpoint of the study is overall response.
Pipeline Analysis and Sales Projections of the Top 25 Pharmaceutical Companies 2013-2023
M2 - Wed Jul 23, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7pjm9m/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. The companies included in the study are: - Pfizer, inc. - Novartis AG - Roche ltd. - Merck & Co., inc. - Sanofi - Glaxosmithkline PLC - Johnson & johnson - Astra Zeneca plc - Eli Lilly and Company - Abbvie, inc. - Teva Pharmaceutical Industries, Ltd. - Amgen, inc. - Bristol-myers Squibb Company - Takeda Pharmaceutical co., LTD - Bayer AG - Novo nordisk - Boehringer Ingelheim gmbh - Daiichi Sankyo - Astellas - Gilead Sciences - Otsuka Pharmaceutical - Merck KGAA - Actavis - Mylan - Baxter international For more information visit http://www.researchandmarkets.com/research/7pjm9m/top_25
